Goodwin advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s offering. Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the Rule 144A offering of 2.00% Convertible Senior Notes due...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Manta Software in its acquisition by IBM. IBM acquired Manta Software Inc – a world-class data lineage platform — to complement its capabilities within...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Advanced Biologics in its merger with Isto Biologics. Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
You must be a Standard 1 Year member to access this content.
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Banco J.P. Morgan S.A. is acting as exclusive financial advisor, Goodwin LLP as exclusive legal advisor, and PWC as exclusive accounting and tax advisor to Acino....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Orionis Biosciences on the collaboration with Genentech. Privately held Orionis Biosciences announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover...
You must be a Standard 1 Year member to access this content.
Goodwin advised Alpha Wave Global on the investment. Alpha Wave Global, alongside Mubadala Capital, invested in Aman Group’s $360 million funding round. The investment values Aman, run...
You must be a Standard 1 Year member to access this content.
Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Nelson Mullins served as legal counsel to Crown, and Goodwin served as legal counsel to Catcha Investment Corp. Crown LNG Holdings AS and Catcha Investment Corp...
You must be a Standard 1 Year member to access this content.
